We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+19.81%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.35B
AUM Growth
+$99.6M
Cap. Flow
+$46.9M
Cap. Flow %
3.47%
Top 10 Hldgs %
51.22%
Holding
199
New
40
Increased
30
Reduced
31
Closed
45

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$43.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
3
BAX icon
Baxter International
BAX
+$15.5M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$13.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$11.5M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$22.7M
2
RLYP
RELYPSA INC COM
RLYP
+$18.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$17.6M
4
CEMP
Cempra, Inc.
CEMP
+$16.2M
5
SHPG
Shire pic
SHPG
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Miscellaneous 10.46%
3 Consumer Staples 0.55%
4 Consumer Discretionary 0.08%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
151
Inogen
INGN
$138M
$5K ﹤0.01%
+125
New +$5.29K
DCOY
152
Decoy Therapeutics
DCOY
$1.78M
– –
0
– –
ADUS icon
153
Addus HomeCare
ADUS
$2.16B
– –
-7,601
Closed -$237K
BCLI
154
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-26,667
Closed -$916K
BCRX icon
155
BioCryst Pharmaceuticals
BCRX
$2.09B
– –
-123,745
Closed -$1.41M
BHC icon
156
CALL
Bausch Health
BHC
$2.12B
– –
-100
Closed -$18K
CAH icon
157
Cardinal Health
CAH
$54.1B
– –
-2,574
Closed -$198K
ELV icon
158
Elevance Health
ELV
$90.6B
– –
-1,436
Closed -$201K
EW icon
159
Edwards Lifesciences
EW
$49.4B
– –
-9,000
Closed -$213K
GILD icon
160
PUT
Gilead Sciences
GILD
$181B
– –
-100,000
Closed -$9.82M
HCA icon
161
HCA Healthcare
HCA
$91.8B
– –
-2,563
Closed -$198K
IRWD icon
162
Ironwood Pharmaceuticals
IRWD
$671M
– –
-102,957
Closed -$899K
IWM icon
163
PUT
iShares Russell 2000 ETF
IWM
$76.9B
– –
-200,000
Closed -$21.8M
NVO
164
PUT
Novo Nordisk
NVO
$188B
– –
-400,000
Closed -$10.8M
PTCT icon
165
CALL
PTC Therapeutics
PTCT
$5.48B
– –
-100,000
Closed -$2.67M
PTCT icon
166
PUT
PTC Therapeutics
PTCT
$5.48B
– –
-1,005,000
Closed -$26.8M
RGEN icon
167
PUT
Repligen
RGEN
$9.86B
– –
-100,000
Closed -$2.79M
SSO icon
168
PUT
ProShares Ultra S&P500
SSO
$8.76B
– –
-1,600,000
Closed -$11.1M
TBT icon
169
ProShares Trust UltraShort Lehman 20+ Year Treasury
TBT
$316M
– –
-12,000
Closed -$520K
UUP icon
170
Invesco DB US Dollar Index Bullish Fund
UUP
$322M
– –
-55,000
Closed -$1.38M
XBI icon
171
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-100
Closed -$6K
XBI icon
172
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-275,000
Closed -$17.1M
XNCR icon
173
PUT
Xencor
XNCR
$1.77B
– –
-50,000
Closed -$612K
VIRX
174
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-3,333
Closed -$567K
SCTL
175
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
– –
-13,450
Closed -$145K
4 5 6
7
8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Perceptive Advisors held 199 positions worth $1.35B, up 8% from $1.25B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors deployed $46.9M of net new capital in Q4 2015, opening 40 new positions and adding to 30 existing holdings. Its largest new stake was Allergan plc: 145,000 shares worth $45.3M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $22.7M trimmed.

  • Perceptive Advisors's largest Q4 2015 buy was Allergan plc: 145,000 shares worth $45.3M.
  • Perceptive Advisors added most to Teva Pharmaceuticals in Q4 2015, an estimated $19.8M increase.
  • Perceptive Advisors's biggest Q4 2015 reduction was Neurocrine Biosciences, cutting an estimated $22.7M.
  • Perceptive Advisors fully exited RELYPSA INC COM in Q4 2015, selling an estimated $18.3M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $1.35B portfolio in Q4 2015.
  • Perceptive Advisors opened 40 new positions and closed 45 in Q4 2015.
  • Perceptive Advisors's portfolio value rose 8% quarter-over-quarter to $1.35B.

Based on Perceptive Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.